Immuneering Corporation Raises $25 Million

Immuneering Corporation, a biopharmaceutical company focused on improving patient outcomes in oncologic and neurologic diseases, has secured $25,000,000 in new investment capital from investors. This funding round marks a significant milestone for the company as it continues to advance its drug development pipeline. Immuneering applies its expertise in translational bioinformatics across all stages of drug development. The company leverages over a decade of experience in generating insights into drug mechanisms of action and patient treatment responses. This foundation has enabled Immuneering to develop a disease-agnostic platform that integrates human data, novel biology, and chemistry to create and progress its wholly-owned pipeline. The company's current development programs in oncology are primarily aimed at providing treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Immuneering's lead product candidate, IMM-1-104, is a highly selective dual-MEK inhibitor designed to further disrupt KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Additionally, the company has six other oncology programs and two neuroscience programs in discovery stages, targeting pathways such as MAPK and mTOR. The newly secured capital will be instrumental in accelerating the development of Immuneering’s emerging pipeline. The funds are expected to support the advancement of its clinical and discovery programs, including the ongoing development of IMM-1-104, and to further build out its disease-agnostic platform. This investment underscores investor confidence in Immuneering's scientific approach and its potential to deliver novel therapies. Looking ahead, Immuneering is positioned to continue expanding its research and development efforts. The company remains committed to utilizing its unique platform to discover and develop innovative treatments, aiming to improve the lives of patients suffering from debilitating oncologic and neurologic conditions.